BUDGET IMPACT ANALYSIS OF INTRODUCING FRUQUINTINIB FOR THE TREATMENT OF PREVIOUSLY TREATED METASTATIC COLORECTAL CANCER IN THE UNITED STATES FROM THE PAYER PERSPECTIVE

被引：0
|
作者：
Hernandez, L. G. [1 ]
Paly, V [1 ]
Li, S. [2 ]
Khanduri, P. [3 ]
Asfaw, A. A. [4 ]
Zou, D. [5 ]
机构：
[1] Takeda Pharmaceut America Inc, Lexington, MA USA
[2] Evidera, Toronto, ON, Canada
[3] Evidera, Waltham, MA USA
[4] Takeda Dev Ctr Amer Inc TDCA, Lexington, MA USA
[5] Evidera, San Francisco, CA USA
来源：
VALUE IN HEALTH | 2024年 / 27卷 / 06期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
EE267
引用
收藏
页码：S106 / S106
页数：1
相关论文
共 50 条
  • [21] BUDGET IMPACT ANALYSIS OF INTRODUCING SUBCUTANEOUS INFLIXIMAB CT-P13 SC FROM THE UK PAYER PERSPECTIVE
    Perry, M.
    Jang, M.
    ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 : 1879 - 1879
  • [22] BUDGET IMPACT ANALYSIS OF AFLIBERCEPT IN YHE TREATMENT OF METASTATIC COLORECTAL CANCER (MCRC) IN POLAND
    Kaczor, M. P.
    Pawlik, D.
    Wojcik, R.
    Glasek, M.
    Pieczonka, A.
    Kraska, A.
    Zelazowski, K.
    VALUE IN HEALTH, 2014, 17 (07) : A621 - A621
  • [23] Bariatric Surgery Coverage: a Comprehensive Budget Impact Analysis from a Payer Perspective
    Swetha R. Palli
    John A. Rizzo
    Natalie Heidrich
    Obesity Surgery, 2018, 28 : 1711 - 1723
  • [24] BUDGET IMPACT ANALYSIS OF INTRODUCTION OF SUBCUTANEOUS INFLIXIMAB IN FRANCE FROM A PAYER PERSPECTIVE
    Pradie, M.
    Hadjadj, C.
    Moreau, Petiteau F.
    VALUE IN HEALTH, 2022, 25 (01) : S81 - S81
  • [25] Bariatric Surgery Coverage: a Comprehensive Budget Impact Analysis from a Payer Perspective
    Palli, Swetha R.
    Rizzo, John A.
    Heidrich, Natalie
    OBESITY SURGERY, 2018, 28 (06) : 1711 - 1723
  • [26] A budget impact analysis of a magnetic sphincter augmentation device for the treatment of medication-refractory mechanical gastroesophageal reflux disease: a United States payer perspective
    Pandolfino, John
    Lipham, John
    Chawla, Amarpreet
    Ferko, Nicole
    Hogan, Andrew
    Qadeer, Rana A.
    SURGICAL ENDOSCOPY AND OTHER INTERVENTIONAL TECHNIQUES, 2020, 34 (04): : 1561 - 1572
  • [27] A budget impact analysis of a magnetic sphincter augmentation device for the treatment of medication-refractory mechanical gastroesophageal reflux disease: a United States payer perspective
    John Pandolfino
    John Lipham
    Amarpreet Chawla
    Nicole Ferko
    Andrew Hogan
    Rana A. Qadeer
    Surgical Endoscopy, 2020, 34 : 1561 - 1572
  • [28] CLINICAL AND BUDGET IMPACT OF USING A TEST TO DETECT KRAS MUTATIONS IN METASTATIC COLORECTAL CANCER PATIENTS IN THE UNITED STATES
    Cheng, I
    Hertz, D.
    Huang, J.
    Poulios, N.
    VALUE IN HEALTH, 2015, 18 (03) : A40 - A40
  • [29] BUDGET IMPACT ANALYSIS OF NANOLIPOSOMAL IRINOTECAN FOR TREATMENT OF PANCREATIC CANCER FOLLOWING PROGRESSION ON GEMCITABINE - A US PAYER PERSPECTIVE
    Becker, C.
    Mamlouk, K.
    Li, H.
    VALUE IN HEALTH, 2016, 19 (07) : A718 - A719
  • [30] The Budget Impact of Including Rucaparib on a US Payer Formulary for the Treatment of Patients with Metastatic Ovarian Cancer
    Wallace, Katrine
    Adamski, Kelly
    Pai, Ashwini
    Rose, Darya
    Chawla, Anita
    PHARMACOECONOMICS, 2021, 39 (02) : 231 - 241
12345